What is Gout?
Gout is a common and intensely painful form of inflammatory arthritis caused by the deposition of monosodium urate (MSU) crystals in joints and surrounding tissues. It typically presents as sudden episodes of severe pain, swelling, redness, and warmth in one or more joints, most classically affecting the first metatarsophalangeal (MTP) joint of the big toe—a presentation historically known as "podagra." Gout affects approximately 4% of adults in the United States and is more prevalent in men, postmenopausal women, and individuals with certain metabolic conditions.
The disease follows a characteristic pattern: acute flares of excruciating joint inflammation that resolve spontaneously within days to weeks, followed by intercritical periods of apparent well-being. Without appropriate treatment, flares become more frequent and prolonged, eventually leading to chronic tophaceous gout—a condition characterized by persistent joint inflammation, tissue damage, and visible deposits of urate crystals (tophi) under the skin and in other tissues.
Gout has been recognized since antiquity, with descriptions dating back to ancient Egypt and Hippocrates, who called it "the unwalkable disease." Historically associated with rich diets and excessive alcohol consumption, it was once known as the "disease of kings." Modern understanding has revealed the complex interplay of genetic predisposition, metabolic factors, dietary influences, and renal function that contribute to hyperuricemia and crystal formation.
The Role of Uric Acid
Uric acid is the end product of purine metabolism in humans. Unlike most mammals, humans lack the enzyme uricase, which converts uric acid to the more soluble allantoin. This evolutionary loss means that humans maintain higher serum uric acid levels than other species, making them susceptible to urate crystal deposition when levels exceed the saturation threshold of approximately 6.8 mg/dL at physiological temperature and pH.
Hyperuricemia—defined as a serum uric acid level above 6.8 mg/dL—is the fundamental prerequisite for gout development. It can result from overproduction of uric acid (approximately 10% of cases), underexcretion by the kidneys (approximately 90% of cases), or a combination of both. Dietary purines from red meat, organ meats, shellfish, and certain beverages (particularly beer and fructose-sweetened drinks) contribute to the uric acid pool, while the kidneys are responsible for excreting approximately two-thirds of the daily uric acid load.
It is important to note that hyperuricemia alone does not equate to gout. Many individuals with elevated uric acid levels never develop symptomatic crystal deposition. Conversely, serum uric acid levels may be normal or even low during an acute gout flare due to the uricosuric effect of inflammatory cytokines. This is why clinical diagnostic tools like the Janssens rule are valuable—they integrate multiple clinical factors rather than relying on uric acid levels alone.
The Janssens Diagnostic Rule
The Janssens diagnostic rule was developed by Dr. Hein J.E.M. Janssens and colleagues and published in the Archives of Internal Medicine in 2010. It was designed as a clinical prediction tool to help primary care physicians diagnose gout without requiring joint aspiration and synovial fluid crystal analysis—the gold standard but often impractical in primary care settings.
The rule was derived from a prospective study of 328 patients presenting with acute monoarthritis in primary care, using joint aspiration results as the reference standard. Seven clinical variables were identified as independent predictors of gout and assigned weighted scores based on their discriminative ability. The total score ranges from 0 to 13 points, with higher scores indicating a greater probability of gout.
Diagnostic Criteria Scoring
| Criterion | Points | Rationale |
|---|---|---|
| Male sex | 2.0 | Gout is 3–4 times more common in men |
| Previous arthritis attack | 2.0 | Recurrent flares are characteristic of gout |
| Onset within 1 day | 0.5 | Rapid onset is typical of crystal arthritis |
| Joint redness | 1.0 | Erythema suggests intense inflammation |
| 1st MTP joint involvement | 2.5 | Classic location for gout (podagra) |
| Hypertension or CVD | 1.5 | Strong association with metabolic syndrome |
| Serum uric acid > 5.88 mg/dL | 3.5 | Hyperuricemia is the primary risk factor |
| Score Range | Interpretation | Post-test Probability |
|---|---|---|
| ≤ 4 points | Gout unlikely | < 2.8% |
| 4 – 8 points | Gout possible, consider further testing | 27 – 80% |
| ≥ 8 points | Gout very likely | > 80% |
Diagnosis of Gout
The definitive diagnosis of gout requires identification of monosodium urate crystals in synovial fluid or tophus material under polarized light microscopy. These needle-shaped crystals demonstrate strong negative birefringence—appearing yellow when parallel to the axis of the compensator and blue when perpendicular. However, joint aspiration is not always feasible, particularly in primary care or when the affected joint is small or difficult to access.
Clinical diagnosis relies on recognizing the characteristic presentation: acute onset of severe monoarticular inflammation (especially in the first MTP joint), peak intensity within 12–24 hours, resolution within 1–2 weeks, and intercritical periods of complete remission. The Janssens diagnostic rule, the 2015 ACR/EULAR classification criteria, and the older Rome and New York criteria provide structured approaches to clinical diagnosis without crystal confirmation.
Imaging modalities can support the diagnosis. Ultrasound may reveal the "double contour sign" (urate deposition on the articular cartilage surface), and dual-energy CT (DECT) can detect urate crystal deposits with high specificity. Plain radiographs may show characteristic "rat-bite" erosions with overhanging edges in advanced disease but are typically normal in early gout.
Treatment Options
Gout treatment addresses two distinct phases: acute flare management and long-term urate-lowering therapy (ULT) to prevent recurrence and complications.
Acute Flare Management
- NSAIDs: Nonsteroidal anti-inflammatory drugs (indomethacin, naproxen, or celecoxib) at full dose are first-line therapy for acute gout flares. They should be started as early as possible and continued until the flare resolves. NSAIDs are contraindicated in patients with renal insufficiency, peptic ulcer disease, or heart failure.
- Colchicine: Most effective when started within 12–36 hours of flare onset. The current recommended regimen is 1.2 mg initially followed by 0.6 mg one hour later (low-dose protocol), which is equally effective and better tolerated than the traditional high-dose regimen. It should be used with caution in patients with renal or hepatic impairment.
- Corticosteroids: Oral prednisone (30–40 mg daily for 5–7 days), intra-articular injection, or intramuscular triamcinolone are effective alternatives when NSAIDs and colchicine are contraindicated or ineffective. They are particularly useful in patients with renal disease.
- IL-1 inhibitors: Anakinra and canakinumab target interleukin-1, the key cytokine driving the inflammatory response to urate crystals. They are reserved for patients who cannot tolerate or fail standard therapies.
Long-term Urate-Lowering Therapy
- Allopurinol: A xanthine oxidase inhibitor that is first-line ULT for most patients. Starting dose should be low (100 mg/day, or 50 mg in renal impairment) and titrated gradually to achieve the target serum uric acid of < 6 mg/dL. HLA-B*5801 testing is recommended before initiation in certain populations due to risk of severe hypersensitivity reactions.
- Febuxostat: Another xanthine oxidase inhibitor used as an alternative to allopurinol. Studies suggest a potential cardiovascular signal, so it is typically reserved for patients who cannot tolerate allopurinol.
- Probenecid: A uricosuric agent that increases renal uric acid excretion. It requires adequate renal function and is contraindicated in patients with nephrolithiasis or uric acid overproduction.
- Pegloticase: A pegylated recombinant uricase for refractory tophaceous gout unresponsive to conventional ULT. Administered intravenously every 2 weeks, it rapidly lowers uric acid but carries risks of infusion reactions and loss of efficacy due to anti-drug antibodies.
Diet Recommendations
Dietary modification is an important adjunct to pharmacological therapy in gout management. While diet alone rarely achieves sufficient uric acid reduction, it can contribute to overall metabolic health and reduce flare frequency:
- Limit high-purine foods: Reduce intake of red meat, organ meats (liver, kidney, sweetbreads), game meats, and certain seafood (anchovies, sardines, mussels, scallops, herring).
- Limit alcohol: Beer is particularly problematic due to its high purine content and the uric acid-raising effect of alcohol. Wine in moderation may be less harmful, but all alcohol should be limited during flares.
- Limit fructose: High-fructose corn syrup in soft drinks and fruit juices raises uric acid levels by increasing purine catabolism. Avoid or minimize sugar-sweetened beverages.
- Increase water intake: Adequate hydration (2–3 liters daily) promotes uric acid excretion and reduces the risk of uric acid kidney stones.
- Favor low-fat dairy: Studies show that low-fat milk and yogurt have a protective effect, potentially lowering gout risk by 40–50%.
- Coffee: Moderate coffee consumption (4–5 cups/day) has been associated with lower serum uric acid levels and reduced gout risk, though the mechanism is not fully understood.
- Cherries: Cherry consumption has been associated with a 35% reduction in gout flare risk. Both sweet cherries and tart cherry extract may be beneficial.
Prevention Strategies
Preventing gout recurrence requires a comprehensive approach that combines lifestyle modification with pharmacological therapy when indicated:
- Maintain a target serum uric acid below 6 mg/dL (or below 5 mg/dL in severe tophaceous gout) through consistent ULT adherence
- Use prophylactic low-dose colchicine (0.6 mg once or twice daily) or low-dose NSAIDs for the first 3–6 months after starting ULT to prevent mobilization flares
- Achieve and maintain a healthy body weight through gradual weight loss (rapid weight loss can trigger flares)
- Review medications that may raise uric acid levels, such as thiazide diuretics and low-dose aspirin, and consider alternatives where possible
- Manage comorbidities including hypertension, diabetes, chronic kidney disease, and hyperlipidemia, which share common pathways with hyperuricemia
Frequently Asked Questions
How accurate is the Janssens diagnostic rule?
The Janssens rule has been validated with a sensitivity of 87% and specificity of 95% at the threshold score of 8. For scores of 4 or less, the negative predictive value is 97%, effectively ruling out gout. It performs best in primary care settings where joint aspiration is not routinely available.
Can gout affect joints other than the big toe?
Yes, while the first MTP joint is the most commonly affected (podagra), gout can affect virtually any joint. Other commonly involved joints include the ankle, knee, wrist, finger, and elbow. In polyarticular gout, multiple joints may be affected simultaneously, which can mimic rheumatoid arthritis or septic arthritis.
Is gout the same as pseudogout?
No. While both are crystal-induced arthropathies, they involve different crystals. Gout is caused by monosodium urate crystals (negatively birefringent under polarized light), while pseudogout (calcium pyrophosphate deposition disease or CPPD) involves calcium pyrophosphate crystals (weakly positively birefringent). CPPD typically affects larger joints like the knee and wrist and is more common in the elderly.
Do all people with high uric acid levels get gout?
No. Hyperuricemia is necessary but not sufficient for gout. Only about 20% of people with hyperuricemia will develop gout over their lifetime. Factors that influence crystal formation include the degree and duration of hyperuricemia, local joint temperature, pH, and genetic factors affecting urate transport and immune responses to crystals.
Can women get gout?
Yes, though gout is less common in premenopausal women because estrogen promotes renal uric acid excretion. After menopause, gout incidence in women increases significantly, approaching that of men. Women with gout are more likely to have renal impairment, diuretic use, and polyarticular involvement as contributing factors.
Should I start urate-lowering therapy after my first gout flare?
Current guidelines recommend ULT for patients with recurrent flares (two or more per year), tophi, urate arthropathy, or renal stones. After a single uncomplicated flare, the decision should be individualized based on patient preferences, comorbidities, and serum uric acid level. Some experts advocate early ULT initiation to prevent cumulative joint damage.